Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer.

Scientific reports - 28 May 2022

Murakami Yuichi, Kusakabe Daiki, Watari Kosuke, Kawahara Akihiko, Azuma Koichi, Akiba Jun, Taniguchi Masahiko, Kuwano Michihiko, Ono Mayumi

Abstract excerpt

Osimertinib, a third-generation EGFR-TKI, has nowadays been applied to non-small cell lung cancer harboring activated EGFR mutation with or without T790M, but ultimately develop resistance to this drug. Here we report a novel mechanism of acquired resistance to osimertinib and the reversal of which could improve the clinical outcomes. In osimertinib-resistant lung cancer cell lines harboring T790M mutation that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, Neoplasm

Share to Cell Adhesion Molecules

Share to Drug Resistance, Neoplasm

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to src-Family Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 35643725
DOI: 10.1038/s41598-022-12995-8
PMCID: PMC9148303

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer.PMID 35643725Read ↗

Acquired resistance mechanisms to osimertinib: The constant battle.Semantic proximity Read ↗

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer CellsSemantic proximity Read ↗

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung CancerSemantic proximity Read ↗

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?Semantic proximity Read ↗

Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies.Semantic proximity Read ↗

Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer.Semantic proximity Read ↗

Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report.Semantic proximity Read ↗

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation.Semantic proximity Read ↗

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies.Semantic proximity Read ↗

Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis.Semantic proximity Read ↗

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.